Andima Moses, Costabile Gabriella, Isert Lorenz, Ndakala Albert J, Derese Solomon, Merkel Olivia M
Department of Pharmacy, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13, 81377 Munich, Germany.
Department of Chemistry, University of Nairobi, P.O. Box 30197-00100, Nairobi, Kenya.
Pharmaceutics. 2018 Nov 15;10(4):232. doi: 10.3390/pharmaceutics10040232.
β-Sitosterol (β-Sit) is a dietary phytosterol with demonstrated anticancer activity against a panel of cancers, but its poor solubility in water limits its bioavailability and therapeutic efficacy. In this study, poly(lactide-co-glycolic acid) (PLGA) and block copolymers of poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA) were used to encapsulate β-Sit into nanoparticles with the aim of enhancing its in vitro anticancer activity. β-Sitosterol-loaded PLGA and PEG-PLA nanoparticles (β-Sit-PLGA and β-Sit-PEG-PLA) were prepared by using a simple emulsion-solvent evaporation technique. The nanoparticles were characterized for size, particle size distribution, surface charge, and encapsulation efficiency. Their cellular uptake and antiproliferative activity was evaluated against MCF-7 and MDA-MB-231 human breast cancer cells using flow cytometry and MTT assays, respectively. β-Sit-PLGA and β-Sit-PEG-PLA nanoparticles were spherical in shape with average particle sizes of 215.0 ± 29.7 and 240.6 ± 23.3 nm, a zeta potential of -13.8 ± 1.61 and -23.5 ± 0.27 mV, respectively, and with narrow size distribution. The encapsulation efficiency of β-Sit was 62.89 ± 4.66 and 51.83 ± 19.72 % in PLGA and PEG-PLA nanoparticles, respectively. In vitro release in phosphate-buffered saline (PBS) and PBS/with 0.2% Tween 20 showed an initial burst release, followed by a sustained release for 408 h. β-Sit-PLGA nanoparticles were generally stable in a protein-rich medium, whereas β-Sit-PEG-PLA nanoparticles showed a tendency to aggregate. Flow cytometry analysis (FACS) indicated that β-Sit-PLGA nanoparticles were efficiently taken up by the cells in contrast to β-Sit-PEG-PLA nanoparticles. β-Sit-PLGA nanoparticles were therefore selected to evaluate antiproliferative activity. Cell viability was inhibited by up to 80% in a concentration range of 6.64⁻53.08 μg/mL compared to the untreated cells. Taken together, encapsulation of β-Sitosterol in PLGA nanoparticles is a promising strategy to enhance its anticancer activity against breast cancer cells.
β-谷甾醇(β-Sit)是一种膳食植物甾醇,已证明对多种癌症具有抗癌活性,但其在水中的低溶解度限制了其生物利用度和治疗效果。在本研究中,聚(丙交酯-共-乙交酯)(PLGA)和聚(乙二醇)-嵌段-聚(乳酸)(PEG-PLA)嵌段共聚物被用于将β-Sit封装到纳米颗粒中,以增强其体外抗癌活性。通过简单的乳液-溶剂蒸发技术制备了负载β-谷甾醇的PLGA和PEG-PLA纳米颗粒(β-Sit-PLGA和β-Sit-PEG-PLA)。对纳米颗粒进行了尺寸、粒径分布、表面电荷和包封率的表征。分别使用流式细胞术和MTT法评估了它们对MCF-7和MDA-MB-231人乳腺癌细胞的细胞摄取和抗增殖活性。β-Sit-PLGA和β-Sit-PEG-PLA纳米颗粒呈球形,平均粒径分别为215.0±29.7和240.6±23.3nm,zeta电位分别为-13.8±1.61和-23.5±0.27mV,且粒径分布狭窄。β-Sit在PLGA和PEG-PLA纳米颗粒中的包封率分别为62.89±4.66%和51.83±19.72%。在磷酸盐缓冲盐水(PBS)和含0.2%吐温20的PBS中的体外释放显示出初始的突释,随后持续释放408小时。β-Sit-PLGA纳米颗粒在富含蛋白质的培养基中通常稳定,而β-Sit-PEG-PLA纳米颗粒显示出聚集的趋势。流式细胞术分析(FACS)表明,与β-Sit-PEG-PLA纳米颗粒相比,β-Sit-PLGA纳米颗粒能被细胞有效摄取。因此,选择β-Sit-PLGA纳米颗粒来评估抗增殖活性。与未处理的细胞相比,在6.64⁻53.08μg/mL的浓度范围内,细胞活力被抑制高达80%。综上所述,将β-谷甾醇封装在PLGA纳米颗粒中是增强其对乳腺癌细胞抗癌活性的一种有前景的策略。